Non-viral vectors for gene-based therapy (original) (raw)

• Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R. & Wixon, J. Gene therapy clinical trials worldwide to 2012 — an update. J. Gene Med. 15, 65–77 (2013).
  CAS PubMed Google Scholar
• Kay, M. A. State-of-the-art gene-based therapies: the road ahead. Nature Rev. Genet. 12, 316–328 (2011).
  CAS PubMed Google Scholar
• Mingozzi, F. & High, K. A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nature Rev. Genet. 12, 341–355 (2011).
  CAS PubMed Google Scholar
• Baum, C., Kustikova, O., Modlich, U., Li, Z. & Fehse, B. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum. Gene Ther. 17, 253–263 (2006).
  CAS PubMed Google Scholar
• Bessis, N., GarciaCozar, F. J. & Boissier, M. C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 11 (Suppl. 1), S10–S17 (2004).
  CAS PubMed Google Scholar
• Waehler, R., Russell, S. J. & Curiel, D. T. Engineering targeted viral vectors for gene therapy. Nature Rev. Genet. 8, 573–587 (2007).
  CAS PubMed Google Scholar
• Thomas, C. E., Ehrhardt, A. & Kay, M. A. Progress and problems with the use of viral vectors for gene therapy. Nature Rev. Genet. 4, 346–358 (2003).
  CAS PubMed Google Scholar
• Bouard, D., Alazard-Dany, D. & Cosset, F. L. Viral vectors: from virology to transgene expression. Br. J. Pharmacol. 157, 153–165 (2009).
  CAS PubMed PubMed Central Google Scholar
• Pack, D. W., Hoffman, A. S., Pun, S. & Stayton, P. S. Design and development of polymers for gene delivery. Nature Rev. Drug Discov. 4, 581–593 (2005).
  CAS Google Scholar
• Mintzer, M. A. & Simanek, E. E. Nonviral vectors for gene delivery. Chem. Rev. 109, 259–302 (2009).
  CAS PubMed Google Scholar
• Putnam, D. Polymers for gene delivery across length scales. Nature Mater. 5, 439–451 (2006).
  CAS Google Scholar
• Davis, M. E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharmaceut. 6, 659–668 (2009).
  CAS Google Scholar
• Gonzalez, H., Hwang, S. J. & Davis, M. E. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug. Chem. 10, 1068–1074 (1999).
  CAS PubMed Google Scholar
• Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nature Biotech. 28, 172–176 (2010). This study carries out a rational design of a siRNA delivery vector and achieved significant improvement in delivery efficiency.
  CAS Google Scholar
• Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107, 1864–1869 (2010).
  CAS PubMed Google Scholar
• Monopoli, M. P., Aberg, C., Salvati, A. & Dawson, K. A. Biomolecular coronas provide the biological identity of nanosized materials. Nature Nanotechnol. 7, 779–786 (2012).
  CAS Google Scholar
• Lee, H. et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nature Nanotechnol. 7, 389–393 (2012).
  CAS Google Scholar
• Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005).
  CAS PubMed Google Scholar
• Anderson, B. R. et al. Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 39, 9329–9338 (2011).
  CAS PubMed PubMed Central Google Scholar
• Kariko, K., Muramatsu, H., Keller, J. M. & Weissman, D. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol. Ther. 20, 948–953 (2012).
  CAS PubMed PubMed Central Google Scholar
• Deleavey, G. F., Watts, J. K. & Damha, M. J. Chemical modification of siRNA. Curr. Protoc. Nucleic Acid Chem. 39, 16.3.1–16.3.22 (2009).
  Google Scholar
• Mehier-Humbert, S. & Guy, R. H. Physical methods for gene transfer: improving the kinetics of gene delivery into cells. Adv. Drug Deliv. Rev. 57, 733–753 (2005).
  CAS PubMed Google Scholar
• Wells, D. J. Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther. 11, 1363–1369 (2004).
  CAS PubMed Google Scholar
• Newman, C. M. & Bettinger, T. Gene therapy progress and prospects: ultrasound for gene transfer. Gene Ther. 14, 465–475 (2007).
  CAS PubMed Google Scholar
• Plank, C. et al. The magnetofection method: using magnetic force to enhance gene delivery. Biol. Chem. 384, 737–747 (2003).
  CAS PubMed Google Scholar
• Zhang, G., Budker, V. G., Ludtke, J. J. & Wolff, J. A. Naked DNA gene transfer in mammalian cells. Methods Mol. Biol. 245, 251–264 (2004).
  CAS PubMed Google Scholar
• Li, W. & Szoka, F. C. Jr. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res. 24, 438–449 (2007).
  PubMed Google Scholar
• Thomas, M. & Klibanov, A. M. Non-viral gene therapy: polycation-mediated DNA delivery. Appl. Microbiol. Biotechnol. 62, 27–34 (2003).
  CAS PubMed Google Scholar
• Lee, C. C., MacKay, J. A., Frechet, J. M. & Szoka, F. C. Designing dendrimers for biological applications. Nature Biotech. 23, 1517–1526 (2005).
  CAS Google Scholar
• Discher, D. E. & Ahmed, F. Polymersomes. Annu. Rev. Biomed. Engineer. 8, 323–341 (2006).
  CAS Google Scholar
• Martin, M. E. & Rice, K. G. Peptide-guided gene delivery. AAPS J. 9, E18–29 (2007).
  CAS PubMed PubMed Central Google Scholar
• Sokolova, V. & Epple, M. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew. Chem. Int. Ed. Engl. 47, 1382–1395 (2008).
  CAS PubMed Google Scholar
• Kawabata, K., Takakura, Y. & Hashida, M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 12, 825–830 (1995).
  CAS PubMed Google Scholar
• McManus, J. J., Radler, J. O. & Dawson, K. A. Observation of a rectangular columnar phase in a DNA–calcium–zwitterionic lipid complex. J. Am. Chem. Soc. 126, 15966–15967 (2004).
  CAS PubMed Google Scholar
• McManus, J. J., Rädler, J. O. & Dawson, K. A. Does calcium turn a zwitterionic lipid cationic? J. Phys. Chem. B 107, 9869–9875 (2003).
  CAS Google Scholar
• Koltover, I., Salditt, T., Radler, J. O. & Safinya, C. R. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science 281, 78–81 (1998). This paper elucidates structural considerations involved in the endosomal escape of DNA mediated by liposomal nanoparticles.
  CAS PubMed Google Scholar
• Wiethoff, C. M. & Middaugh, C. R. Barriers to nonviral gene delivery. J. Pharm. Sci. 92, 203–217 (2003).
  CAS PubMed Google Scholar
• Morille, M., Passirani, C., Vonarbourg, A., Clavreul, A. & Benoit, J. P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29, 3477–3496 (2008).
  CAS PubMed Google Scholar
• Capecchi, M. R. High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. Cell 22, 479–488 (1980).
  CAS PubMed Google Scholar
• Miller, A. M. & Dean, D. A. Tissue-specific and transcription factor-mediated nuclear entry of DNA. Adv. Drug Deliv. Rev. 61, 603–613 (2009).
  CAS PubMed Google Scholar
• Varga, C. M. et al. Quantitative comparison of polyethylenimine formulations and adenoviral vectors in terms of intracellular gene delivery processes. Gene Ther. 12, 1023–1032 (2005).
  CAS PubMed Google Scholar
• Dinh, A. T., Pangarkar, C., Theofanous, T. & Mitragotri, S. Understanding intracellular transport processes pertinent to synthetic gene delivery via stochastic simulations and sensitivity analyses. Biophys. J. 92, 831–846 (2007).
  CAS PubMed Google Scholar
• Wasungu, L. & Hoekstra, D. Cationic lipids, lipoplexes and intracellular delivery of genes. J. Control. Release 116, 255–264 (2006).
  CAS PubMed Google Scholar
• Godbey, W. T., Wu, K. K. & Mikos, A. G. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc. Natl Acad. Sci. USA 96, 5177–5181 (1999).
  CAS PubMed Google Scholar
• Breunig, M. et al. Gene delivery with low molecular weight linear polyethylenimines. J. Gene Med. 7, 1287–1298 (2005).
  CAS PubMed Google Scholar
• Schaffer, D. V., Fidelman, N. A., Dan, N. & Lauffenburger, D. A. Vector unpacking as a potential barrier for receptor-mediated polyplex gene delivery. Biotechnol. Bioeng. 67, 598–606 (2000).
  CAS PubMed Google Scholar
• Cohen, R. N., van der Aa, M. A., Macaraeg, N., Lee, A. P. & Szoka, F. C. Jr. Quantification of plasmid DNA copies in the nucleus after lipoplex and polyplex transfection. J. Controlled Release 135, 166–174 (2009).
  CAS Google Scholar
• Gill, D. R., Pringle, I. A. & Hyde, S. C. Progress and prospects: the design and production of plasmid vectors. Gene Ther. 16, 165–171 (2009).
  CAS PubMed Google Scholar
• Gill, D. R. et al. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1α promoter. Gene Ther. 8, 1539–1546 (2001).
  CAS PubMed Google Scholar
• Wooddell, C. I., Reppen, T., Wolff, J. A. & Herweijer, H. Sustained liver-specific transgene expression from the albumin promoter in mice following hydrodynamic plasmid DNA delivery. J. Gene Med. 10, 551–563 (2008).
  CAS PubMed Google Scholar
• Miao, C. H. et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol. Ther. 1, 522–532 (2000).
  CAS PubMed Google Scholar
• Argyros, O. et al. Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Ther. 15, 1593–1605 (2008).
  CAS PubMed Google Scholar
• Kreiss, P. et al. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res. 27, 3792–3798 (1999).
  CAS PubMed PubMed Central Google Scholar
• Darquet, A. M. et al. Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther. 6, 209–218 (1999).
  CAS PubMed Google Scholar
• Kay, M. A., He, C. Y. & Chen, Z. Y. A robust system for production of minicircle DNA vectors. Nature Biotech. 28, 1287–1289 (2010).
  CAS Google Scholar
• Ehrhardt, A., Xu, H., Huang, Z., Engler, J. A. & Kay, M. A. A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase. Mol. Ther. 11, 695–706 (2005).
  CAS PubMed Google Scholar
• Wu, S. C. et al. PiggyBac is a flexible and highly active transposon as compared to Sleeping Beauty, Tol2, and Mos1 in mammalian cells. Proc. Natl Acad. Sci. USA 103, 15008–15013 (2006).
  CAS PubMed Google Scholar
• Aronovich, E. L., McIvor, R. S. & Hackett, P. B. The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum. Mol. Genet. 20, R14–R20 (2011).
  CAS PubMed PubMed Central Google Scholar
• Fraley, R., Subramani, S., Berg, P. & Papahadjopoulos, D. Introduction of liposome-encapsulated SV40 DNA into cells. J. Biol. Chem. 255, 10431–10435 (1980).
  CAS PubMed Google Scholar
• Felgner, P. L. et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl Acad. Sci. USA 84, 7413–7417 (1987). References 59 and 60 are the earliest studies to show lipid-mediated DNA delivery in vitro.
  CAS PubMed Google Scholar
• Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nature Rev. Drug Discov. 8, 129–138 (2009).
  CAS Google Scholar
• Lonez, C., Vandenbranden, M. & Ruysschaert, J. M. Cationic liposomal lipids: from gene carriers to cell signaling. Prog. Lipid Res. 47, 340–347 (2008).
  CAS PubMed Google Scholar
• Hersey, P. & Gallagher, S. Intralesional immunotherapy for melanoma. J. Surg. Oncol. 109, 320–326 (2014).
  CAS PubMed Google Scholar
• Olins, D. E., Olins, A. L. & Von Hippel, P. H. Model nucleoprotein complexes: studies on the interaction of cationic homopolypeptides with DNA. J. Mol. Biol. 24, 157–176 (1967).
  CAS PubMed Google Scholar
• Laemmli, U. K. Characterization of DNA condensates induced by poly(ethylene oxide) and polylysine. Proc. Natl Acad. Sci. USA 72, 4288–4292 (1975).
  CAS PubMed Google Scholar
• Wu, G. Y. & Wu, C. H. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem. 262, 4429–4432 (1987).
  CAS PubMed Google Scholar
• Wu, G. Y. & Wu, C. H. Receptor-mediated gene delivery and expression in vivo. J. Biol. Chem. 263, 14621–14624 (1988). References 66 and 67 are among the first to investigate the possibility of targeted non-viral nucleic acid delivery in vitro and in vivo.
  CAS PubMed Google Scholar
• Choi, Y. H. et al. Polyethylene glycol-grafted poly-L-lysine as polymeric gene carrier. J. Control. Release 54, 39–48 (1998).
  PubMed Google Scholar
• Kim, S. W. Polylysine copolymers for gene delivery. Cold Spring Harb.Protoc. 2012, 433–438 (2012).
  PubMed Google Scholar
• Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505–515 (2008).
  CAS PubMed PubMed Central Google Scholar
• Bazile, D. et al. Stealth Me. PEG–PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84, 493–498 (1995).
  CAS PubMed Google Scholar
• Konstan, M. W. et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum. Gene Ther. 15, 1255–1269 (2004).
  CAS PubMed Google Scholar
• Lungwitz, U., Breunig, M., Blunk, T. & Gopferich, A. Polyethylenimine-based non-viral gene delivery systems. Eur. J. Pharm. Biopharm. 60, 247–266 (2005).
  CAS PubMed Google Scholar
• Boussif, O. et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92, 7297–7301 (1995). This is the first paper to show that PEI can facilitate DNA transfection in vitro and in vivo.
  CAS PubMed Google Scholar
• Godbey, W. T., Wu, K. K. & Mikos, A. G. Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J. Biomed. Mater. Res. 45, 268–275 (1999).
  CAS PubMed Google Scholar
• Wightman, L. et al. Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. J. Gene Med. 3, 362–372 (2001).
  CAS PubMed Google Scholar
• Goula, D. et al. Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther. 5, 1291–1295 (1998).
  CAS PubMed Google Scholar
• Kircheis, R., Wightman, L. & Wagner, E. Design and gene delivery activity of modified polyethylenimines. Adv. Drug Deliv. Rev. 53, 341–358 (2001).
  CAS PubMed Google Scholar
• Coll, J. L. et al. In vivo delivery to tumors of DNA complexed with linear polyethylenimine. Hum. Gene Ther. 10, 1659–1666 (1999).
  CAS PubMed Google Scholar
• Lv, H., Zhang, S., Wang, B., Cui, S. & Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114, 100–109 (2006).
  CAS PubMed Google Scholar
• Nguyen, H. K. et al. Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents. Gene Ther. 7, 126–138 (2000).
  CAS PubMed Google Scholar
• Petersen, H. et al. Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system. Bioconjug. Chem. 13, 845–854 (2002).
  CAS PubMed Google Scholar
• Breunig, M., Lungwitz, U., Liebl, R. & Goepferich, A. Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc. Natl Acad. Sci. USA 104, 14454–14459 (2007).
  CAS PubMed Google Scholar
• Thomas, M. & Klibanov, A. M. Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells. Proc. Natl Acad. Sci. USA 99, 14640–14645 (2002).
  CAS PubMed Google Scholar
• Fortune, J. A., Novobrantseva, T. I. & Klibanov, A. M. Highly effective gene transfection in vivo by alkylated polyethylenimine. J. Drug Deliv. 2011, 204058 (2011).
  PubMed PubMed Central Google Scholar
• Zangi, L. et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nature Biotech. 31, 898–907 (2013).
  CAS Google Scholar
• Kormann, M. S. et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nature Biotech. 29, 154–157 (2011). References 86 and 87 show the therapeutic potential of delivery of modified mRNA in vivo.
  CAS Google Scholar
• Su, X., Fricke, J., Kavanagh, D. G. & Irvine, D. J. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol. Pharm. 8, 774–787 (2011).
  CAS PubMed PubMed Central Google Scholar
• Phua, K. K., Leong, K. W. & Nair, S. K. Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. J. Control. Release 166, 227–233 (2013).
  CAS PubMed PubMed Central Google Scholar
• Kanasty, R. L., Whitehead, K. A., Vegas, A. J. & Anderson, D. G. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol. Ther. 20, 513–524 (2012).
  CAS PubMed PubMed Central Google Scholar
• Layzer, J. M. et al. In vivo activity of nuclease-resistant siRNAs. RNA 10, 766–771 (2004).
  CAS PubMed PubMed Central Google Scholar
• Jackson, A. L. & Linsley, P. S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nature Rev. Drug Discov. 9, 57–67 (2010).
  CAS Google Scholar
• Nguyen, D. N. et al. Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc. Natl Acad. Sci. USA 109, E797–E803 (2012).
  CAS PubMed Google Scholar
• Whitehead, K. A., Dahlman, J. E., Langer, R. S. & Anderson, D. G. Silencing or stimulation? siRNA delivery and the immune system. Annu. Rev. Chem. Biomol. Eng. 2, 77–96 (2011).
  CAS PubMed Google Scholar
• Wang, A. Z., Langer, R. & Farokhzad, O. C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63, 185–198 (2012).
  CAS PubMed Google Scholar
• Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotech. 25, 1149–1157 (2007).
  CAS Google Scholar
• Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357–1364 (2010).
  CAS PubMed PubMed Central Google Scholar
• Malek, A. et al. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol. Appl. Pharmacol. 236, 97–108 (2009).
  CAS PubMed Google Scholar
• Huang, Y. et al. Elimination pathways of systemically delivered siRNA. Mol. Ther. 19, 381–385 (2011).
  CAS PubMed Google Scholar
• Rozema, D. B. et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl Acad. Sci. USA 104, 12982–12987 (2007).
  CAS PubMed Google Scholar
• Kanasty, R., Dorkin, J. R., Vegas, A. & Anderson, D. Delivery materials for siRNA therapeutics. Nature Mater. 12, 967–977 (2013).
  CAS Google Scholar
• Zuckerman, J. E., Choi, C. H., Han, H. & Davis, M. E. Polycation–siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc. Natl Acad. Sci. USA 109, 3137–3142 (2012).
  CAS PubMed Google Scholar
• Naeye, B. et al. In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier. Biomaterials 34, 2350–2358 (2013).
  CAS PubMed Google Scholar
• Aird, W. C. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circul. Res. 100, 158–173 (2007).
  CAS Google Scholar
• Wisse, E., Jacobs, F., Topal, B., Frederik, P. & De Geest, B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 15, 1193–1199 (2008).
  CAS PubMed Google Scholar
• Maeda, H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 21, 797–802 (2010).
  CAS PubMed Google Scholar
• Yu, B., Zhao, X., Lee, L. J. & Lee, R. J. Targeted delivery systems for oligonucleotide therapeutics. AAPS J. 11, 195–203 (2009).
  CAS PubMed PubMed Central Google Scholar
• Salvati, A. et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nature Nanotechnol. 8, 137–143 (2013).
  CAS Google Scholar
• Sahay, G. et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nature Biotech. 31, 653–658 (2013). This study elucidates the mechanism of cellular uptake of LNPs and the importance of exocytosis in limiting delivery efficiency.
  CAS Google Scholar
• Schwarz, D. S. et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199–208 (2003).
  CAS PubMed Google Scholar
• Geisbert, T. W. et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375, 1896–1905 (2010).
  CAS PubMed Google Scholar
• Zimmermann, T. S. et al. RNAi-mediated gene silencing in non-human primates. Nature 441, 111–114 (2006).
  CAS PubMed Google Scholar
• Wheeler, J. J. et al. Stabilized plasmid–lipid particles: construction and characterization. Gene Ther. 6, 271–281 (1999).
  CAS PubMed Google Scholar
• Morrissey, D. V. et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotech. 23, 1002–1007 (2005).
  CAS Google Scholar
• Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 51, 8529–8533 (2012).
  CAS PubMed PubMed Central Google Scholar
• Akinc, A. et al. Development of lipidoid–siRNA formulations for systemic delivery to the liver. Mol. Ther. 17, 872–879 (2009).
  CAS PubMed PubMed Central Google Scholar
• Alabi, C. A. et al. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery. Proc. Natl Acad. Sci. USA 110, 12881–12886 (2013).
  CAS PubMed Google Scholar
• Burnett, J. C., Rossi, J. J. & Tiemann, K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 6, 1130–1146 (2011).
  CAS PubMed PubMed Central Google Scholar
• Fitzgerald, K. et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383, 60–68 (2014).
  CAS PubMed Google Scholar
• Santel, A. et al. A novel siRNA–lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 13, 1222–1234 (2006).
  CAS PubMed Google Scholar
• Santel, A. et al. RNA interference in the mouse vascular endothelium by systemic administration of siRNA–lipoplexes for cancer therapy. Gene Ther. 13, 1360–1370 (2006).
  CAS PubMed Google Scholar
• Aleku, M. et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 68, 9788–9798 (2008).
  CAS PubMed Google Scholar
• Landen, C. N. Jr. et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910–6918 (2005).
  CAS PubMed Google Scholar
• Davis, M. E. et al. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr. Med. Chem. 11, 179–197 (2004).
  CAS PubMed Google Scholar
• Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E. & Triche, T. J. Sequence-specific knockdown of EWS–FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984–8992 (2005).
  CAS PubMed Google Scholar
• Bartlett, D. W. & Davis, M. E. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng. 99, 975–985 (2008).
  CAS PubMed Google Scholar
• Heidel, J. D. et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl Acad. Sci. USA 104, 5715–5721 (2007).
  CAS PubMed Google Scholar
• Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067–1070 (2010). This paper provides the first evidence that systemically administered siRNA can induce RNAi in humans.
  CAS PubMed PubMed Central Google Scholar
• Wong, S. C. et al. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid. Ther. 22, 380–390 (2012).
  CAS PubMed PubMed Central Google Scholar
• Rozema, D. B., Ekena, K., Lewis, D. L., Loomis, A. G. & Wolff, J. A. Endosomolysis by masking of a membrane-active agent (EMMA) for cytoplasmic release of macromolecules. Bioconjug.Chem. 14, 51–57 (2003).
  CAS PubMed Google Scholar
• Wooddell, C. I. et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 21, 973–985 (2013).
  CAS PubMed PubMed Central Google Scholar
• Yasuda, M. et al. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Proc. Natl Acad. Sci. USA http://dx.doi.org/10.1073/pnas.1406228111 (2014).
• Chen, K. & Rajewsky, N. The evolution of gene regulation by transcription factors and microRNAs. Nature Rev. Genet. 8, 93–103 (2007).
  CAS PubMed Google Scholar
• Pritchard, C. C., Cheng, H. H. & Tewari, M. MicroRNA profiling: approaches and considerations. Nature Rev. Genet. 13, 358–369 (2012).
  CAS PubMed Google Scholar
• Hydbring, P., Badalian-Very, G. Clinical applications of microRNAs F1000Res. 2, 136 (2013).
  PubMed PubMed Central Google Scholar
• Nana-Sinkam, S. P. & Croce, C. M. Clinical applications for microRNAs in cancer. Clin. Pharmacol. Ther. 93, 98–104 (2013).
  CAS PubMed Google Scholar
• He, L. et al. A microRNA component of the p53 tumour suppressor network. Nature 447, 1130–1134 (2007).
  CAS PubMed PubMed Central Google Scholar
• Trang, P. et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 19, 1116–1122 (2011).
  CAS PubMed PubMed Central Google Scholar
• Bader, A. G. miR-34 — a microRNA replacement therapy is headed to the clinic. Front. Genet. 3, 120 (2012).
  CAS PubMed PubMed Central Google Scholar
• Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397–405 (2013).
  CAS PubMed PubMed Central Google Scholar
• Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S. & Gregory, P. D. Genome editing with engineered zinc finger nucleases. Nature Rev. Genet. 11, 636–646 (2010).
  CAS PubMed Google Scholar
• Boch, J. et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326, 1509–1512 (2009).
  CAS PubMed Google Scholar
• Moscou, M. J. & Bogdanove, A. J. A simple cipher governs DNA recognition by TAL effectors. Science 326, 1501 (2009).
  CAS PubMed Google Scholar
• Miller, J. C. et al. A TALE nuclease architecture for efficient genome editing. Nature Biotech. 29, 143–148 (2011).
  CAS Google Scholar
• Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
  CAS PubMed PubMed Central Google Scholar
• Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).
  CAS PubMed PubMed Central Google Scholar
• Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910–918 (2013).
  CAS PubMed PubMed Central Google Scholar
• Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380–1389 (2013).
  CAS PubMed PubMed Central Google Scholar
• Li, H. et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475, 217–221 (2011). This study is the first to show that genome editing tools (ZFN) can modify gene in vivo and rescue disease phenotype.
  CAS PubMed PubMed Central Google Scholar
• Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotech. 32, 551–553 (2014). This paper is the first to show that the Cas9 system can correct a disease mutation and rescue disease phenotype in adult animals.
  CAS Google Scholar
• Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727–730 (2002).
  CAS Google Scholar
• Heyes, J., Palmer, L., Bremner, K. & MacLachlan, I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107, 276–287 (2005).
  CAS PubMed Google Scholar
• Ambegia, E. et al. Stabilized plasmid-lipid particles containing PEG–diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim. Biophys. Acta 1669, 155–163 (2005).
  CAS PubMed Google Scholar
• Mishra, S., Heidel, J. D., Webster, P. & Davis, M. E. Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes. J. Control. Release 116, 179–191 (2006).
  CAS PubMed Google Scholar
• Bellocq, N. C., Pun, S. H., Jensen, G. S. & Davis, M. E. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug. Chem. 14, 1122–1132 (2003).
  CAS PubMed Google Scholar
• Mishra, S., Webster, P. & Davis, M. E. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol. 83, 97–111 (2004).
  CAS PubMed Google Scholar
• Ramalingam, S., Annaluru, N. & Chandrasegaran, S. A CRISPR way to engineer the human genome. Genome Biol. 14, 107 (2013).
  PubMed PubMed Central Google Scholar